{"id":"implanon","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Irregular bleeding or amenorrhea"},{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Breast tenderness"},{"rate":"5-10","effect":"Mood changes"},{"rate":"1-5","effect":"Insertion site pain or infection"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1697750","moleculeType":"Small molecule","molecularWeight":"324.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Implanon® is a subdermal implant containing etonogestrel, a synthetic progestin that suppresses the luteinizing hormone (LH) surge required for ovulation. The implant provides continuous hormone release over three years, also increasing cervical mucus viscosity to impede sperm transport. This dual mechanism achieves contraceptive efficacy exceeding 99%.","oneSentence":"Implanon® releases a steady dose of the progestin etonogestrel subdermally to prevent ovulation and thicken cervical mucus, providing long-acting reversible contraception.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:14.544Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Long-acting reversible contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT06775626","phase":"EARLY_PHASE1","title":"Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel","status":"SUSPENDED","sponsor":"Maíta Poli de Araújo","startDate":"2025-04-01","conditions":"Menstrual Symptoms","enrollment":40},{"nctId":"NCT04669678","phase":"PHASE4","title":"Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-17","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":110},{"nctId":"NCT05742503","phase":"","title":"Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-03-30","conditions":"Progesterone, Contraceptive Methods","enrollment":80},{"nctId":"NCT00725413","phase":"PHASE4","title":"A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-11","conditions":"Contraception","enrollment":210},{"nctId":"NCT00620464","phase":"PHASE3","title":"A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Contraception","enrollment":108},{"nctId":"NCT05174195","phase":"NA","title":"Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?","status":"TERMINATED","sponsor":"University Hospital, Geneva","startDate":"2016-08-15","conditions":"Contraception, Progestogen Adverse Reaction","enrollment":67},{"nctId":"NCT02357368","phase":"PHASE4","title":"Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk","status":"COMPLETED","sponsor":"Lisa Haddad","startDate":"2015-02","conditions":"HIV, Contraception","enrollment":59},{"nctId":"NCT02669238","phase":"PHASE2, PHASE3","title":"Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2018-05-25","conditions":"Endometriosis","enrollment":2},{"nctId":"NCT03336346","phase":"","title":"Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-11-15","conditions":"Contraceptive Usage, HIV Infections, Drug Interaction","enrollment":148},{"nctId":"NCT01299116","phase":"PHASE4","title":"Long-Acting Reversible Contraception","status":"COMPLETED","sponsor":"FHI 360","startDate":"2011-12","conditions":"Contraception","enrollment":916},{"nctId":"NCT03264781","phase":"PHASE1, PHASE2","title":"The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2016-08","conditions":"Uterine Bleeding","enrollment":44},{"nctId":"NCT00828542","phase":"NA","title":"Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-07","conditions":"Breastfeeding, Contraception","enrollment":40},{"nctId":"NCT02144259","phase":"NA","title":"The Impact of Contraception on Postpartum Weight Loss","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-04","conditions":"Weight","enrollment":100},{"nctId":"NCT02469454","phase":"PHASE4","title":"Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2015-06","conditions":"Contraception, Newborn, Child Development","enrollment":100},{"nctId":"NCT01968135","phase":"PHASE2","title":"Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":"Uterine Hemorrhage, Contraception","enrollment":32},{"nctId":"NCT01920022","phase":"PHASE4","title":"Quickstart of Nexplanon® at Medical Abortion","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2013-10","conditions":"Early Pregnancy Termination, Medical Abortion, Postabortion Contraception","enrollment":551},{"nctId":"NCT02416687","phase":"PHASE4","title":"Etonogestrel Implant and Postpartum Insertion","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-03","conditions":"Contraception","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":389,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexplanon®"],"phase":"marketed","status":"active","brandName":"Implanon®","genericName":"Implanon®","companyName":"FHI 360","companyId":"fhi-360","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Implanon® releases a steady dose of the progestin etonogestrel subdermally to prevent ovulation and thicken cervical mucus, providing long-acting reversible contraception. Used for Long-acting reversible contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}